272 related articles for article (PubMed ID: 33797754)
21. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
22. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Qayoom H; Wani NA; Alshehri B; Mir MA
Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
[TBL] [Abstract][Full Text] [Related]
23. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
24. HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/β-catenin signaling.
Yu L; Wang C; Pan F; Liu Y; Ren X; Zeng H; Shi Y
Biomed Pharmacother; 2019 Oct; 118():109361. PubMed ID: 31545274
[TBL] [Abstract][Full Text] [Related]
25. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway inhibition.
Xiao G; Lu W; Yuan J; Liu Z; Wang P; Fan H
J Transl Med; 2024 Jan; 22(1):99. PubMed ID: 38268032
[TBL] [Abstract][Full Text] [Related]
26. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
27. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
28. SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial-mesenchymal transition by β-catenin and Beclin1/autophagy signaling in colorectal cancer.
Zhu Y; Huang S; Chen S; Chen J; Wang Z; Wang Y; Zheng H
Cell Death Dis; 2021 May; 12(5):449. PubMed ID: 33953166
[TBL] [Abstract][Full Text] [Related]
29. Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling.
Cui Y; Ma W; Lei F; Li Q; Su Y; Lin X; Lin C; Zhang X; Ye L; Wu S; Li J; Yuan Z; Song L
J Pathol; 2016 Jul; 239(3):297-308. PubMed ID: 27060981
[TBL] [Abstract][Full Text] [Related]
30. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
31. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
32. The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
Wang W; Rana PS; Markovic V; Sossey-Alaoui K
Breast Cancer Res; 2023 Mar; 25(1):31. PubMed ID: 36949468
[TBL] [Abstract][Full Text] [Related]
33. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway.
Zhang J; Xu HD; Xing XJ; Liang ZT; Xia ZH; Zhao Y
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5315-5322. PubMed ID: 31298383
[TBL] [Abstract][Full Text] [Related]
34. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
Hu J; Lai Y; Huang H; Ramakrishnan S; Pan Y; Ma VWS; Cheuk W; So GYK; He Q; Geoffrey Lau C; Zhang L; Cho WCS; Chan KM; Wang X; Rebecca Chin Y
Br J Cancer; 2022 Jan; 126(1):57-71. PubMed ID: 34718356
[TBL] [Abstract][Full Text] [Related]
35. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract][Full Text] [Related]
36. SHC4 orchestrates β-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting Src kinase autophosphorylation.
Zhong W; Jian Y; Zhang C; Li Y; Yuan Z; Xiong Z; Huang W; Ouyang Y; Chen X; Song L; Liu P; Wang X
Cancer Lett; 2024 Feb; 582():216516. PubMed ID: 38052369
[TBL] [Abstract][Full Text] [Related]
37. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
38. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
39. YAP1-induced RBM24 promotes the tumorigenesis of triple-negative breast cancer through the β-catenin pathway.
Chen X; Lin X; Xia X; Xiang X
J Investig Med; 2024 Jun; 72(5):403-413. PubMed ID: 38441112
[TBL] [Abstract][Full Text] [Related]
40. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]